closedosingdownloadefficacymoasafetytable-checktable-cross

The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

PROVEN EFFICACY IN TREATING NAIL PSORIASIS1*

Sustained improvement in nail psoriasis up to 1 year1,a,b

aESTEEM 1 study. Data as observed; includes patients initially randomized to OTEZLA 30 mg BID or placebo at week 0 who were PASI-75 responders at week 32 and continued to receive OTEZLA through week 52

bAt week 16, mean percent improvement in NAPSI score was significantly greater with OTEZLA 30 mg BID (22.5%, n = 339) vs placebo (-6.5%, n = 178). P < 0.0001; FAS, LOCF.

See the OTEZLA difference

Real patients, real pictures.

Baseline

Week 16

Individual results may vary.

Week 32

Individual results may vary.

*In patients with nail psoriasis at baseline (NAPSI score ≥1; 558/844, 66.1%).

Actual OTEZLA patient.

 BID, twice daily; BL, baseline; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; FAS, full analysis set; LOCF, last observation carried forward; NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity Index.

OTEZLA IMPROVES NAIL PSORIASIS2,3

Sustained improvement in NAPSI score2,3,a

aLIBERATE study. Includes patients with NAPSI score ≥1 at baseline with a baseline value and a post-baseline value at the study week. Missing scores were imputed using the LOCF methodology. Mean NAPSI score at baseline was 4.14 (placebo) and 4.18 (OTEZLA).

bP = 0.4959, OTEZLA vs placebo.

Nail psoriasis continues to improve for up to 2 years with OTEZLA2,3

References:

  1. Reich K, Goodfield, M, Green L, et al. Efficacy and safety of apremilast through 104 weeks in subjects with moderate to severe psoriasis randomized to placebo, apremilast, or etanercept who continued on or switched to apremilast after week 16 on a phase 3b study. Presented at: the 2017 ACR/ARHP Annual Meeting: November 3-8, 2017; San Diego, CA.
  2. Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31(3):507-517.
  3. Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018;32(3):397-402.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 51 Countries
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Singapore

  • Kuwait

  • Taiwan

  • UAE

  • Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil